ArrayExpress Uploader0human1278040.5195no U2AF1 mutation46, XY[20]2.38/3/2005642GoodmaleRA1.48.9CD34+ purified MDS bone marrowmyelodysplastic syndrome0White2005-08-033008130243U2AF1 mutation46, XX[20]2.77/12/2005412GoodfemaleRA1.212.2CD34+ purified MDS bone marrowmyelodysplastic syndrome3White2005-04-263218642.556U2AF1 mutation47,XX,+8[20]1.910/3/20056312IntermediatefemaleRAEB0.39.8CD34+ purified MDS bone marrowmyelodysplastic syndrome0White2005-10-033504600.537no U2AF1 mutation46, XY[20]2.111/17/2006304GoodmaleRA1.67.5CD34+ purified MDS bone marrowmyelodysplastic syndrome0Black2006-11-173724400123no U2AF1 mutation46,XY[20]2.95/5/2006592GoodmaleRA1.413.8CD34+ purified MDS bone marrowmyelodysplastic syndrome0White5/5/2006421452122no U2AF1 mutation46,XX[20]3.311/4/20053310GoodfemaleRAEB0.98.3CD34+ purified MDS bone marrowmyelodysplastic syndrome2White2005-09-3043113728no U2AF1 mutation46,XY,add(3)(q25),del(3)(p13),del(5)(q15q31),-6,+8,add(12)(p11.2),add(15)(p11.1), -18,+22[cp4]/44,sl,-8,-20,-22,+mar[cp5]/44,sl1,-del(3),-7,+2mar[cp5]/43,sl1,add(X)(q28),-add(12p),+12,-mar[cp6]6.58/29/2006547PoormaleRAEB4.68.2CD34+ purified MDS bone marrowmyelodysplastic syndrome1White2006-07-05497942124no U2AF1 mutation46,XY,der(1;22)(q10;q10)[4]/46,XY[16]4.11/18/2006470IntermediatemaleRA1.68.6CD34+ purified MDS bone marrowmyelodysplastic syndrome0White2006-01-18667720161no U2AF1 mutation46,XX[20]5.15/9/20066510GoodfemaleRAEB2.38.8CD34+ purified MDS bone marrowmyelodysplastic syndrome0White2006-05-017036530.527no U2AF1 mutation46,XX[20]32/2/2005200GoodfemaleRA0.68.4CD34+ purified MDS bone marrowmyelodysplastic syndrome0White2005-02-02705782128no U2AF1 mutation46,XY[20]3.38/4/2006345GoodmaleRAEB1.79.7CD34+ purified MDS bone marrowmyelodysplastic syndrome0White2006-08-04843623164U2AF1 mutation46,XY,del(20)(q11.2q13.3)[2]/46,XY[18]0.73/3/2003596GoodmaleRAEB0.49.7CD34+ purified MDS bone marrowmyelodysplastic syndrome0White2003-03-039170110.5107U2AF1 mutation46,XY,del(20)(q11.2)[12]/46,XY[8]3.36/2/2006800GoodmaleRA0.58.2CD34+ purified MDS bone marrowmyelodysplastic syndrome0White2006-06-02937954335U2AF1 mutation47,XY,+8[1]/47,idem,del(16)(q12.1)[13]/48,idem,+Y,del(16)(q11.1)[5]/46,XY[1]1.29/20/20055012PoormaleRAEB0.39.9CD34+ purified MDS bone marrowmyelodysplastic syndrome0White2005-09-12989739352U2AF1 mutation46,XY,del(7)(q21)[8]/46,XY[12]1.29/30/20057118PoormaleRAEB0.211CD34+ purified MDS bone marrowmyelodysplastic syndrome1White2005-08-15not specifiedunknownunknowncontrolunknownunknownunknownunknownunknownunknownunknownunknownunknownunknownCD34+ purified control bone marrowcontrolunknownunknownunknownnot specifiedunknownunknowncontrolunknownunknownunknownunknownunknownunknownunknownunknownunknownunknownCD34+ purified control bone marrowcontrolunknownunknownunknownnot specifiedunknownunknowncontrolunknownunknownunknownunknownunknownunknownunknownunknownunknownunknownCD34+ purified control bone marrowcontrolunknownunknownunknownnot specifiedunknownunknowncontrolunknownunknownunknownunknownunknownunknownunknownunknownunknownunknownCD34+ purified control bone marrowcontrolunknownunknownunknown4143arrayexpress_sid4Myelodysplastic syndromes (MDS) are a heterogenous group of hematopoietic stem cell disorders characterized by dysplastic blood cell...E-GEOD-30195/profile/8773/arrayexpressuploader1919acute myeloid leukemiablood cellbonebone marrowcellleukemiamyeloid leukemiaperipheralstem cellDec.12, 2014FalseE-GEOD-30195_A-AFFY-44gene-expression-profiling-in-myelodysplastic-syndrGene expression profiling in myelodysplastic syndromesSep.16, 2014Myelodysplastic syndromes (MDS) are a heterogenous group of hematopoietic stem cell disorders characterized by dysplastic blood cell formation and peripheral blood cytopenias. Up to 30% of patients with MDS will progress to a highly chemotherapy-resistant secondary acute myeloid leukemia (sAML). We identified mutations in U2AF1 in MDS patients and patients with U2AF1 mutations are at an increased risk of developing sAML. We identified mutations in U2AF1 in patients with MDS and hypothesized that U2AF1 mutations may represent a novel mechanism that could alter gene expression in MDS. To elucidate gene expression changes associated with U2AF1 mutations, we analyzed the global mRNA expression profile obtained from bone marrow CD34+ cells purified from 5 MDS patients with a U2AF1 mutation, 10 MDS patients without a mutation, and 4 normal donors.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-30195http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-30195/samples/